FOXO4-DRI

In senescent cells, the transcription factor FOXO4 binds p53 and sequesters it in the nucleus, preventing p53 from triggering apoptosis. This FOXO4-p53 interaction is specifically upregulated only in senescent cells. FOXO4-DRI mimics the FOXO4 binding domain and competitively disrupts this interaction, freeing p53 to relocate to mitochondria where it activates the intrinsic apoptotic pathway. Since healthy cells do not have elevated FOXO4-p53 binding, they are unaffected.

The D-retro-inverso (DRI) design uses D-amino acids (mirror images of natural L-amino acids) arranged in reverse sequence. This creates a peptide that maintains a similar side-chain topology to the original L-peptide, allowing it to interact with the same biological targets, but with dramatically increased resistance to proteolytic degradation. Natural proteases cannot efficiently cleave D-amino acid bonds, extending the peptide half-life significantly.

FOXO4-DRI protocols typically involve short, intermittent cycles rather than continuous use. A common research protocol is 5-20 mg administered 3 times weekly for a 2-4 week loading period, followed by rest periods of several months. The goal is to clear accumulated senescent cells in targeted cycles, as senescent cells take weeks to months to re-accumulate. Some protocols include a lower maintenance dose of once weekly after the initial loading phase.

In the landmark 2017 Cell publication, FOXO4-DRI treatment of naturally aged mice (equivalent to ~90 human years) resulted in restored fitness levels, regrowth of fur density, and improved renal function. In a fast-aging mouse model (XpdTTD/TTD), it counteracted doxorubicin chemotherapy-induced senescence and reduced liver toxicity. Treated mice showed significant reduction in senescence markers (p16INK4a, p21) and improvements in multiple healthspan indicators.